摘要
目的探讨IL-6在卵巢癌诊断及预后判断中的作用。方法选择2004年1月至2006年12月在汕头大学医学院第一附属医院住院的未接受任何治疗的卵巢癌患者54例为研究组,其中Ⅰ-Ⅱ期15例,Ⅲ期39例,选择卵巢良性肿瘤患者22例和体检健康妇女18例为良性对照组和正常对照组,ELISA法检测血清中IL-6水平。结果①研究组血清IL-6水平显著高于卵巢良性肿瘤组和正常对照组(P<0.05);②研究组中Ⅲ期患者血清中IL-6水平明显高于Ⅰ-Ⅱ期(P<0.05);③化疗后血清中IL-6水平明显下降(P<0.05)。结论IL-6在卵巢癌的诊断中有一定的特异性,并可应用于临床分期的判定;IL-6不能作为判断化疗停药和复发的肿瘤标志物。
Objective To explore the effect of Interleukin-6 in diagnosis and prognosis of ovarian carcinoma. Methods 54 cases with ovarian carcinoma as study group,which 15 cases in Ⅰ - Ⅱ stage and 39 cases in Ⅲ stage,and 22 cases with ovarian benign and 18 normal women as control groups. All cases were selected from First Hospital of Medical College of Shantou University from 2004-1 to 2006-12. The levels of IL-6 in serum were measured by enzyme-labeled immunosorbent assay （ELISA）. Results （1）The levels of IL-6 in serum in study group were significantly higher than those in controls group （ P 〈 0.05） .（2）In study group, the levels of IL-6 in serum in Ⅲ stage were significantly higher than that in Ⅰ - Ⅱ stages （ P 〈 o. 05）. （3）The levels of IL-6 in serum were significantly lower after chemical therapy. Condusion IL-6 has much valuable in diagnosis of ovarian carcinoma, and also in determines of clinic stage. But IL-6 was not as a tumor marker of to decide the effect of chemical therapy.
出处
《中国实验诊断学》
2007年第5期652-654,共3页
Chinese Journal of Laboratory Diagnosis
关键词
卵巢癌
白细胞介素-6
临床分期
化疗
ovarian carcinoma
Interleukin-6
Clinic- stage
Chemical therapy
